Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARMA: ctDNA Adaptive Risk Maintenance in Bladder Cancer
NCT06050954Phase 2Withdrawn
- Sponsor
- Fox Chase Cancer Center
- Start
- Sep 2023
- Primary completion
- Jan 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label trial of pembrolizumab in urothelial carcinoma (UC) (2 arms), sponsored by Fox Chase Cancer Center. Primary endpoint: Proportion of patients who are progression-free and alive at 6 months. Planned start Sep 2023; status: withdrawn.
02
Drugs
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT06050954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06050954.